Last checked at 29 Jun 2017 13:53
29 June 2017 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that it was notified on 26 June 2017 that Chris Meredith, who is a Director and PDMR, following the successful achievement of certain performance criteria, has exercised 162,069 options from the Long Term Incentive Plan (LTIP). Mr Meredith subsequently sold 76,604 Ordinary Shares of 5p each on 26 June 2017 at a share price of 301.8015p per Ordinary Share to cover the tax payable on this exercise.
As a result of these transactions Chris Meredith's beneficial interest in the Company has increased from 1,384,841 shares to 1,470,306 shares.
Long Term Incentive Plan (LTIP)
Director | No. of LTIPs prior to exercise | LTIPs exercised | Ordinary Shares sold | Ordinary shares retained | LTIPs after exercise |
Chris Meredith, Chief Executive Officer | 583,509 | 162,069 | 76,604 | 85,465 | 421,440 |
Overall Holding
Director | Holding prior to exercise | Number of shares exercised | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Chris Meredith, Chief Executive Officer | 1,384,841 | 162,069 | 76,604 | 301.8015p | 1,470,306 | 0.69% |
The Company further announces that it was notified on 26 June 2017 that Mary Tavener, who is a Director and PDMR, following the successful achievement of certain performance criteria, has exercised 162,069 options from the Long Term Incentive Plan (LTIP). Mrs Tavener subsequently sold 54,519 Ordinary Shares of 5p each on 26 June 2017 at a share price of 301.8015p per Ordinary Share to cover the tax payable on this exercise.
As a result of these transactions Mary Tavener's beneficial interest in the Company has increased from 1,890,647 shares to 1,954,191 shares.
Long Term Incentive Plan (LTIP)
Director | No. of LTIPs prior to exercise | LTIPs exercised | Ordinary Shares sold | Ordinary shares retained | LTIPs after exercise |
Mary Tavener, Chief Financial Officer | 442,265 | 114,440 | 54,519 | 63,544 | 327,825 |
Overall Holding
Director | Holding prior to exercise | Number of shares exercised | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Mary Tavener, Chief Financial Officer | 1,890,647 | 114,440 | 54,519 | 301.8015p | 1,954,191 | 0.92% |
The Company further announces that it was notified on 26 June 2017 that Jeff Willis, who is a Senior Manager and PDMR, following the successful achievement of certain performance criteria, has exercised 38,450 options from the Long Term Incentive Plan (LTIP). Following this transaction the beneficial ownership of Jeff Willis is as follows:
Long Term Incentive Plan (LTIP)
PDMR | No. of LTIPs prior to exercise | LTIPs exercised | Ordinary shares retained | LTIPs after exercise |
Jeff Willis | 161,044 | 38,450 | 38,450 | 122,594 |
Overall Holding
PDMR | Holding prior to exercise | Number of shares exercised | Resultant holding | % of issued share capital |
Jeff Willis | 130,085 | 38,450 | 168,535 | 0.08% |
The Company further announces that it was notified on 26 June 2017 that Simon Coates, who is a Senior Manager and PDMR, following the successful achievement of certain performance criteria, has exercised 27,783 options from the Long Term Incentive Plan (LTIP). Mr Coates has also exercised 7,888 Ordinary Shares of 5p from the Deferred Share Bonus Plan (DSB). Mr Coates subsequently sold 17,448 Ordinary Shares of 5p each on 26 June 2017 at a share price of 301.8015p per Ordinary Share to cover the tax payable on these exercises.
Following these transactions the beneficial ownership of Simon Coates is as follows:
Long Term Incentive Plan (LTIP)
PDMR | No. of LTIPs prior to exercise | LTIPs exercised | Ordinary shares retained | LTIPs after exercise |
Simon Coates | 101,409 | 27,783 | 10,335 | 73,626 |
Deferred Share Bonus Plan (DSB)
PDMR | No. of DSBs prior to exercise | DSBs exercised | Ordinary Shares sold | DSBs after exercise |
Simon Coates | 42,825 | 7,888 | Nil | 34,937 |
Overall Holding
PDMR | Holding prior to exercise | Number of shares exercised | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Simon Coates | 73,481 | 35,671 | 17,448 | 301.8015p | 91,704 | 0.04% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Chris Meredith | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 162,069 shares from the Long Term Incentive Plan · Sale of 76,604 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 76,604 Aggregated price: £3.018015 | ||||
e) | Date of the transaction: 26/06/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Mary Tavener | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 199,319 shares from the Long Term Incentive Plan · Sale of 148,423 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 54,519 Aggregated price: £3.018015 | ||||
e) | Date of the transaction: 26/06/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Jeff Willis | ||||
2. | Reason for the notification | ||||
a) | Position/status: Senior Manager/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transaction: · Exercise of 38,450 shares from the Long Term Incentive Plan | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 26/06/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Simon Coates | ||||
2. | Reason for the notification | ||||
a) | Position/status: Senior Manager/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 27,783 shares from the Long Term Incentive Plan · Exercise of 7,888 shares from the Deferred Share Bonus Plan · Sale of 17,448 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 17,448 Aggregated price: £3.018015 | ||||
e) | Date of the transaction: 26/06/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys | AMS@consilium-comms.com |
Investec Bank plc(NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Daniel Adams / Patrick Robb |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 600 employees. For more information, please see www.admedsol.com.